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Introduction
Atrial fibrillation (AF) is the most common clinically relevant cardiac
arrhythmia. The estimated prevalence in the general population is
1–2% and increases with age.1–8
Patients with AF are at increased risk of thromboembolism, in par-
ticular ischaemic stroke. The risk of stroke in patients with non-
valvular (essentially non-rheumatic) AF is5% per year.9 Moreover,
strokes related toAF are associatedwith a highermortality andmor-
bidity when compared with non-AF strokes, emphasizing the need
for more effective stroke prevention in these patients.10
The CHADS2 score (cardiac failure, hypertension, age, diabetes,
stroke counted double) was established to assess the risk of thrombo-
embolic events in patients with AF of non-valvular origin.11 Although
there is a clear relationship between the CHADS2 score and stroke
rate, the CHA2DS2-VASc score has recently been introduced and
adopted by the European Society of Cardiology (ESC) as well as by
American Heart Association, American College of Cardiology, and
Heart Rhythm Society and other national bodies’ guidelines for AF in
an attempt to improve risk stratification in the low-risk group by con-
sidering additional stroke risk factors (gender, vascular disease) in add-
ition to old factors including cardiac failure, hypertension, age (divided
to two risk classes) diabetes, and stroke that may influence a decision
for anticoagulation therapy.12
Prospective and randomized studies show that oral anticoagula-
tion (OAC) significantly reduces the risk of thromboembolism.13
However, this treatment is underutilized in patients with AF due to
poor patient compliance, contraindications, and potential bleeding
complications.14–18
The pathogenesis of thrombogenesis in AF is multifactorial and
includes the Virchow triad of events leading to thrombus formation,
i.e. endothelial or endocardial damage or dysfunction, abnormal blood
stasis, and altered haemostasis, platelet function, and fibrinolysis.19
There is evidence forendothelial damage, aswell as intensefibrosis
and inflammation in the left atrium (LA) in patients with AF.20 These
changes are especially prominent in the left atrial appendage (LAA), a
particularly low flow area, and may enhance to thrombus formation
by their effect on the endocardial surface.21,22
There is also strong evidence for the presence of a prothrombotic
and hypercoagulable state in AF, as manifested by increased blood
levels of markers reflecting coagulation activity (prothrombin frag-
ments 1 and2, fibrinopeptideA, thrombin–antithrombin complexes,
and D dimer).23,24
The LAA is the remnant of the embryonic LA. The LAA is a tubular
blind-ended structurewithdifferent lobes andvariablemorphology. Its
complex structurewith areasof relative lowflowpredisposes to stasis,
especially during AF when blood flow velocity decreases, as can be
visualized on transoesophageal echocardiography (TOE) examination
with spontaneous contrast (smoke) or on pulsed-wave Doppler
during paroxysms of AF.25–28 It has been shown that in patients with
non-valvular AF, 90% of thrombi are located in the LAA.29 Thrombi
detected in the LAA as well as a reduced LAA peak flow velocity
were identified as independent predictors of an increased thrombo-
embolic risk,30,31 and also for recurrenceof strokeamongnon-valvular
AF patients recovering from ischaemic stroke.32
Moreover, patients with certain LAA morphologies have been
shown to have different levels of thrombo-embolic risk further sup-
porting the role of LAA in embolization.33
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Left atrial appendage occlusion or exclusion in AF34–50 is based on
theconcept thatonly10%of clinically relevant emboli innon-valvular
AF do not originate in the LAA.51–61 The rationale is that, after exclud-
ing the LAA as an embolic source, the remaining small risk does not
longer warrant OAC with its inherent risk for major bleeds. The risk
of embolism from the LAA or the LA increases with age, but so does
the risk of bleeding under OAC. Various surgical and catheter-based
methods have been developed to exclude the LAA and the success
of catheter-based methods attests to the validity of this concept.62
This document reviews the catheter-based methods and their results.
History
Surgical techniques for left atrial
appendage exclusion
Incidental surgical LAA exclusions during heart surgery have been
performed for decades.63 A first report by Madden dates back to
1949.34 The popularity of this procedure remained low as it did
prolong the surgical procedure and required some specific techni-
ques. Moreover, follow-up TOE often detected residual flow in the
LAA in case of a simple suture64 and in a large number of these
patients the need for lifelong OAC with a vitamin K antagonist
(VKA) remained due to indications unrelated to AF, most commonly
mechanical valve prostheses in themitral position. An electrocardio-
graphically guided thoracoscopic technique for isolated surgical LAA
occlusion65 and a percutaneous endocardial/epicardial approach
(Lariat, SentreHeart)46,47,50 where an epicardial sling suture is
guided by a magnet inside the LAA have been introduced more re-
cently. In addition, a number of other minimally invasive surgical
and percutaneous devices including the AtriClip, Cardioablate, and
Aegis, are at various stages of advanced animal studies or first in
man experiments.
Catheter-based left atrial appendage
occlusion
The electrophysiologist Michael Lesh conceived a device called
PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlu-
sion) for percutaneous plugging of the LAA, intrigued by the fact that
during ablation of AF the LAAwas easily accessible. He assisted Horst
Sievert’s first such intervention on 30 August 2001.38 The PLAATO
device (Medtronic) had a number of significant drawbacks and the
implantation technique was fairly difficult and perilous. The device
was pulled off the market although clinical results were favourable.43
On 15 June 2002, percutaneous LAA occlusion without general
anaesthesia or echocardiographic guidance in awake patients was
introduced by Bernhard Meier using the technically simpler Amplat-
zer approach41 and taking advantage of the double-disc devices rou-
tinely used for occlusion of an atrial septal defect (ASD) or a patent
foramen ovale (PFO). The disc destined for the right side of the
interatrial septum in ASD or PFO occlusion covered the entrance
of the LAA not unlike the plate of a pacifier outside a toddler’s
mouth (pacifier principle). Subsequently, the Amplatzer devices
and introducer sheaths (St Jude) were adapted for LAA occlusion.
The dedicated Amplatzer Cardiac Plug (ACP) and LAA sheath
were introduced in 2008.
On 12August 2002, theWatchman device (Boston Scientific) was
introduced into clinical practice by Eugen Hauptmann and Eberhard
Grube. It has since undergone several modifications and is approved
in many countries worldwide. It remains the only device studied in
randomized trials, such as PROTECT AF45 and the PREVAIL.66 In
December 2013, an Food and Drug Administration (FDA) advisory
committee voted favourably for approval of this device for use in
the USA as an alternative to warfarin.
The WaveCrest device (Johnson and Johnson) has recently
receivedCEmark, aswell. Itwasdevelopedwith separatelyapplicable
fixation anchors and a different design intended to provide more
superficial deployment at the entrance to LAA with little or no ma-
nipulation within the LAA body.
Since 2010, a percutaneously inserted intra-LAA patch has been
used by a group around Eleftherios Sideris.49Other devices, current-
ly in early animal or human trials, have beendeveloped by,Occlutech,
Gore, and Lifetech.
The feasibility of the mentioned Lariat non-surgical combined
endocardial/epicardial suture ligation of the LAA was first demon-
strated in animals by Lee et al. in 2010,46 then in humans by Bartus
et al.47 in 2011, and subsequently evaluated in clinical routine. The
device has CE mark and is approved by the FDA.
Currently available devices and
techniques including some surgical
techniques
Avarietyof surgical approacheshave been examinedmainly in obser-
vational studies and with mixed results.37,40,42,64,67 Two alternative
concepts to achieve LAA occlusion are obstruction of the LAA
orifice with an occlusion device41,45,48,68 or percutaneous suture
ligation using an endocardial/epicardial approach.47
Currently, three entirely catheter-based devices are commercially
used for mechanical orifice obstruction, the Watchman and
WaveCrest devices and theACP. The Lariat device is used for percu-
taneous endocardial/epicardial suture ligation.46,47,50 They all have
obtained CE mark.
The Watchman device consists of a nitinol cage (Figure 1) with a
160 mm polyethylene terephthalate(PTFE) membrane covering the
surface facing the LA. Fixation barbs are attached to the portion
facing the circumference of the appendage minimizing the risk of dis-
lodgement and embolization. It is attached to a delivery cable and
delivered via a 14 French (F, outer diameter 4.7 mm) access sheath.
A single curve or double curve configuration sheath can be used de-
pending on the appendage orientation. After transseptal puncture (a
low posterior puncture location is preferred to allow coaxial align-
mentwith the appendage), intravenousheparin is administeredmain-
taining an activated clotting time (ACT).250 s and a pigtail catheter
is positioned into the LAA over a soft J-tipped 0.035 inch wire. Angi-
ography of the LA focusing on the LAA is performed in several views
[right anterior oblique (RAO) caudal and cranial projections typically
outline the LAA best], delineating shape and size. Sizing of the device,
taking advantage of both cine angiography and TOE, is discussed
under the ‘Imaging for left atrial appendage occlusion’ section. The
device size is typically chosen 10–20% larger than the diameter of
the landing zone (measured from the area of the left circumflex
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coronary artery across the LAA to1 cm inward from the tip of the
ridge separating LAA and left upper pulmonary vein). Subsequently,
an extra-stiff J tipped 0.035 inch wire is advanced into the distal LAA
and the pigtail catheter and transseptal sheath are exchanged for the
access sheathwhilemaintainingwire position. Someoperators intro-
duce a catheter into the left upper pulmonary vein first instead of
aiming at the LAA. In this case, after transseptal puncture, an extra-
stiff 0.035 inch wire is positioned into the left upper pulmonary
vein and the transseptal sheath is exchanged over the wire for the
access catheter. Subsequently, a pigtail catheter is advanced
through the access sheath to the LAA. The access sheath has three
markers corresponding to device size and is advanced into the
LAA until the marker aligns with the ostial plane of the appendage.
After purging, the device is advanced via a delivery catheter to the
distal end of the access sheath. Finally, the access sheath and delivery
catheter are slowly withdrawn while maintaining device position,
allowing it to unfold. Once deployed, appropriate position is con-
firmed by both angiography and TOE. A tug test is performed
under fluoroscopy or TOE demonstrating simultaneous movement
of the device and appendage. Optimally, the device should not pro-
trude .4–7 mm beyond the LAA ostium (depending on device
size outlined in the manufacturer’s instructions for use manual) and
should cover the entire ostium with no or minimal (,5 mm by
colour Doppler) residual flow and a compression grade of 8–20%
(some recommend a higher compression grade of 15–30%). The
compression grade is expressed in per cent comparing the diameter
of the implanted devicewith the unconstricted diameter indicated by
the manufacturer in the size label. When optimal positioning is con-
firmed, the device is released. If position or size appears suboptimal,
the device can be retrieved and exchanged or repositioned. Table 1
lists the basic steps of LAA device implantation.
The Amplatzer ACP consists of a cylindrical nitinol cage (lobe)
securing the device in the LAA body connected by a short flexible
waist to a nitinol plate (disc) covering the appendage ostium. Both
are laid in with polyester fabric (Figure 2). Similar to the Watchman
device, the cage is surrounded by fixation hooks. The flexible waist
facilitates positioning and conformation to variable and complex
appendage shapes. Of note, contrary to the Watchman device, the
length of the ACP is shorter than its diameter. Therefore, whereas
the Watchman device cannot be implanted in appendages shorter
than wide, the ACP may be an option under those circumstances.
In fact, ACP implantation can be attempted in virtually all appendages.
Themore recently introduced Amulet generation of that devicemay
Table 1 Step-by-step device implantation
Transoesophageal or intracardiac echocardiography immediately prior to the procedure to rule out LAA thrombus (contraindication for the procedure)
(1) Femoral venous access
(2) Transseptal puncture (typically in an inferoposterior location)
Heparin via the sheath or intravenously with maintenance of a goal ACT of.250 s (some prefer heparin administration prior to transseptal puncture)
(3) Sheath access to the LAA (either option a or b)
(a) A pigtail catheter is advanced into the LAA (and angiography performed) and subsequently exchanged over a stiff guidewire for the delivery sheath
(b) A catheter (typically a multipurpose catheter) is advanced into the left upper pulmonary vein, and exchanged over a stiff guidewire for the delivery
sheath. A pigtail catheter is advanced via the delivery sheath into the LAA (and angiography performed) and subsequently the delivery sheath is
advanced over the pigtail catheter into the LAA
(4) LAA measurements are made and the appropriate device size is chosen (10–20% larger than the landing zone diameter)
(5) The sheath is advanced over a stiff guidewire (in case of option 3a) or the pigtail catheter (in case of option 3b) until the proximal marker corresponding
with the device size matches the LAA ostium
(6) The stiff guidewire (in case of option 3a) or pigtail catheter (in case of option 3b) is removed
(7) Blood is allowed to exit the sheath while holding the sheath hub and flush line as low as possible (below the patient’s anticipatedmidline of the chest) to
eliminate any air trapped in the sheath
(8) Device preparation (generous flushing of the device within the delivery catheter)
(9) The delivery catheter and device are advanced until the distal marker of the delivery catheter and delivery sheath match
(10) The sheath is gradually pulled back as a unit while maintaining delivery cable position to allow the device to unfold
(11) Position is confirmed via echocardiography and fluoroscopy and a tug test is performed
(12) Device release (e.g. delivery cable turned counter clockwise)
ACT, activated clotting time; LAA, left atrial appendage.
Figure 1 Watchman LAA occlusion device.
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improve ease and safety of use and further expands the size range of
appendages that can fit the device.69 It also has dimensional changes
that are intended to improve stability and occlusion of the LAA os by
the disc. The device fits landing zones from 11 to 31 mm. Femoral
venous access (sheath sizes 9–14 F inner diameter depending on
the device size and type), transseptal puncture, LAA angiography,
and TOE imaging as well as delivery sheath positioning are as previ-
ously outlined (Table 1). The sheath may alternatively be directly
advanced into the LAA. Like the Watchman device, the ACP is re-
trievable prior to disconnection from the pusher cable.With the de-
livery sheath at least 15 mm inside the LAA, the first half of the device
(lobe) is deliveredby sheath retraction and the secondhalf by pushing
it out. Then, the disc is produced by further retracting the sheath
while still gently pushing on the device. With optimal positioning,
the lobe should be visibly compressed (tire shape) with an appre-
ciable distance to the disc, connected by a stretchable waist. The
disc should assume a slightly concave shape and cover the entire
LAAostiumor at leastmostof it (pacifier principle). After a sustained
tug test and confirmation of an optimal position, the ACP is released.
The WaveCrest device consists of a nitinol structure without
exposed metal hub and with a foam layer facing the LAA to
promote rapid organization and a PTFE layer facing the LA to
reduce thrombus formation (Figure 3). It is conformable to LAA
anatomy and fixation anchors are separately actionable and radially
positioned to provide effective fixation at the appendage once the
desired position in attained. The WaveCrest delivery sheath is
designed to optionally position the occluder in the LAA ostium
during deployment and anchoring. Of note, the delivery sheath is
not intended for deep access and manipulation inside the appendage
as the device is designed and intended for proximal placement.
Should the Watchman or the ACP devices be deemed too large
for very short appendages, the WaveCrest may provide an alterna-
tive. As previously described for the Watchman and ACP devices
(Table 1), LA access is provided by a 12 F sheath in the femoral vein
and a preferably posterior transseptal puncture. The measurements
of the projected landing zone on TOE include the distance from the
left circumflex coronary artery to 10 mm distal to the apex of the
lateral ridge (coumadin ridge). Most importantly, measurements
should include the widest part of the ostium, since the positioning
has to be in the proximal end of the LAAmouth, allowing headroom
for anchors. Measurement at 08, 458, 908, and 1358 are recom-
mended to capture the long axis and short axis of the ostium and
the 1358 viewusually shows thewidest diameter. Themoreproximal
positioning of the WaveCrest device is related to the concept that
distal deployment may compress the device itself and the anchors.
Over-compressed anchors may become entangled. Therefore, a
position proximal to all lobes guarantees best occlusion and the
risk of pericardial effusion is minimized. Before detaching the
device, the sheath needs to be pulled back2 cm from the occluder
and contrast medium is injected through the delivery system port to
visualize the distal LAA. A tug on the delivery catheter is performed
until movement is seen (device and tissue move as a unit). In case
repositioning appears necessary, the hooks are withdrawn before
moving the device. After these steps, the device is set free.
The endocardial/epicardial Lariat approach to LAA occlusion
leaving no foreign material in the heart is more complicated. A lasso-
like suture, (snare), is positionedbyapercutaneous technique epicar-
dially at thebaseof the LAAand tightened followedby suture ligation.
First, epicardial access is obtained similar to epicardial access for elec-
trophysiological ablations70 and an epicardial soft tipped 14 F access
cannula inserted into the pericardial space. Secondly, femoral venous
access is established and transseptal puncture performed. Via an 8.5 F
delivery sheath (e.g. SL 1 transseptal catheter by St Jude), a specially
designed magnet tipped 0.025 inch endocardial guide wire is
advanced into the LAA apex followed by a balloonmounted (compli-
ant 20 mm balloon) catheter. The position of the endocardial guide
wire is confirmed via contrast medium injection through the
balloon catheter lumen. Via the percutaneous epicardial access
sheath, a second0.035 inchmagnet tippedepicardialwire is advanced
towards the LAA and aligned with a magnet located at the distal end
of the endocardial wire already located in the LAA apex. The balloon
in the LAA is inflated to help identify the appendage ostium and allow
a lasso delivered via the epicardial sheath over the epicardial wire to
grab the LAAostium. Finally, the lasso is tightened.Appendage occlu-
sion is confirmed by TOE and fluoroscopic imaging and a suture is
deployed. The epicardial and endocardial delivery systems are
Figure 2 Amplatzer Cardiac Plug.
Figure 3 WaveCrest device.
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removed. Subsequent necrosis of the strangulated LAA is likely but
apparently not a problem.
Table 2 provides tips and tricks for use during implantation of
intravascular LAA occluders.
Imaging for left atrial appendage
occlusion
Adequate implementation of various imaging modalities is essential
for developing a successful LAAocclusion programme. Imaging is im-
portant for pre-procedural and periprocedural assessment of the
LAA and for follow-up. The LAA can occasionally be visualized
with transthoracic echocardiography (TTE) but usually requires
TOE, intracardiac echocardiography (ICE), cardiac magnetic reson-
ance imaging (MRI), or computerized tomography (CT). Transoeso-
phageal echocardiography is an integral part for guidance inmost but
not all41 LAA occlusion publications. Imaging modalities continue to
evolve. The value of newer modalities should be compared against
TOE, the gold standard for imaging the LAA and guiding LAA
occlusion procedures.
Pre-procedural assessment
It is important to confirm the absence of LAA thrombi prior to LAA
occlusion. The presence of mobile thrombi is a contraindication for
percutaneous LAA occlusion, since dislodgement of thrombus may
occur withmanipulation of sheaths or devices in the LAA. Currently,
TOE is considered the reference technique for the detection of
thrombi in the LAA.71 In most patients, the LAA can be adequately
visualized using TOE. Yet, in some patients there may be difficulties
in obtaining unequivocal images, as for example, in patients with
prominent pectinate muscles which may be falsely interpreted as
LAA thrombus. The incidence of LAA thrombus on TOE among
patients undergoing AF ablation who have been adequately anticoa-
gulated was found to be very low and in those patients an elevated
CHADS2 score was the strongest predictor of LAA thrombus.
72
The prevalence of LA or LAA thrombus or sludge (dynamic gelatin-
ous, precipitous echodensity without a discrete mass) in patients
undergoing TOE examination for pulmonary vein isolation increased
from 0% in patients with CHADS2 score of 0–11% in patients with
CHADS2 score of 4–6.
72 Of note, the prevalence of LAA thrombus
may be higher in patients scheduled for LAAocclusion, since patients
Table 2 Tips and tricks for LAA device implantation
(1) Using a PFO for transseptal access may lead to suboptimal delivery sheath alignment with the LAA. Sometimes this problem can be solved by custom
shaping the sheath with or without hot air gun
(2) Minimize device sheath time in the LA especially in large LA with LAA sludge and/or pronounced smoke (longer indwelling gear time increases
device-associated thrombus risk)
(3) Minimize the risk of air embolism
(a) Generously backbleed the transseptal and access/delivery sheath allowing air to exit the sheath prior to inserting any equipment or devices (keep the
haemostatic valve and device armbelow themidlineof the chest). Keeping the haemostatic valve, proximal sheath end, and side armunderwatermay
prevent air entering the system during backbleeding
(b) Remove dilators, catheters, and transseptal puncture needles slowly
(c) Flush the device and delivery catheter generously prior to insertion
(4) Choosing a device
(a) Avoid implanting a Watchman device if the LAA length is less than the device diameter
(b) Avoid implanting a Watchman device if the LAA diameter is ,17 or .30 mm
(c) Avoid implanting an ACP if the landing zone diameter is .29 mm (31 for Amulet)
(d) Avoid implanting an ACP if the LAA length is ,10 mm (7.5 for Amulet)
(e) If the LAA is too large for either theWatchman or ACP (but the maximal diameter ,40 mm), suture occlusion with the Lariat technique could be
considered
(f) Avoid Lariat suture ligation in patientswith a superiorly oriented LAAor in LAAs that course behind the pulmonary artery (removal of the Lariat loop
may be challenging or impossible). Use of the Lariat is contraindicated in patients with prior heart surgery (due to pericardial adhesions) andmay be
exceedingly difficult or impossible in patients with pectus excavatum
(5) Confirm adequate position
Watchman
(a) The shoulder should not protrude beyond the LAA ostium by .20% of its diameter (,4.2 mm for a 21 mm device,,4.8 mm for a 24 mm device,
,5.4 mm for a 27 mm device, ,6 mm for a 30 mm device, and ,6.6 mm for a 33 mm device)
(b) Assure optimal compression (10–20%) by both TOE and fluoroscopy
(c) Do not accept residual leaks of .3 mm
(d) Look in all standard TOE views (see above)
ACP
(a) Assure slightly concave disc shape
(b) Optimally, the lobe should be slightly compressed (tyre-shaped), no compression or deformity suggests a too small size or too proximal position,
whereas too much compression with significant alteration of the shape suggests too large size or too distal positioning
(c) The lobe should not protrude more than one-third beyond the left circumflex coronary artery
(d) Optimally, the disc and lobe should be separated slightly
(e) Look in all standard TOE views (08, 308, 458, 908, and 1358 for adequate seal and coverage of all lobes)
ACP, Amplatzer Cardiac Plug; LA, left atrium; LAA, left atrial appendage; TOE, transoesophageal echocardiography.
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may not be anticoagulated because of previous bleeding complica-
tions. The diagnostic performance of a dual-enhanced cardiac CT
protocol for detection of LAA thrombi was studied in patients with
stroke.73–76 The overall sensitivity and specificity of CT for the de-
tection of thrombi in the LAA were 96 and 100%, respectively.74
The role of cardiac MRI in management pathways for diagnosing
LAA thrombus77 is not well enough defined and further studies are
required. Ad hoc LAA occlusion using LA angiography for thrombus
exclusion has been described in a small series.78
Pre-proceduralTOEalreadyhints to thedevicesizeorshouldreveal
if the LAA appears difficult or impossible to occlude. The LAA is best
imaged fromthemid-oesophageal view.Using themultiplane function,
the LAA is interrogated in multiple views (08, 458, 908, and 1358). The
morphologyandpresenceofmultiple lobesof theLAAareusuallyonly
appreciated at an angle beyond 1008. Characterization of the LAA
shape and the presence of multiple lobes can be facilitated by three-
dimensional (3D) TOE or pre-procedural MRI or CT.
Watchman and ACP devices require specific TOE measurements
necessary for choosing the appropriate device sizes. The maximal
width of the LAA ostium and depth of the LAA are first measured
(Figure 4). The maximum LAA ostium width is measured from the
level of the left circumflex coronary artery to a point 1–2 cm from
the tip of the left superior pulmonary vein limbus (at 08) and from
the mitral annulus to a point 1–2 cm from the limbus (458, 908,
and 1358). The ostium of the LAA usually has an oval shape. It is
recommended to use the diameter of the longest axis (generally
superoinferior). The depth of the LAA is measured from the
ostium line to the apex of the LAA. The Watchman device can be
used if the maximum LAA ostium is .17 or ,31 mm, the ACP if it
is,28 mm (for larger diameters, deeper placementmay be an alter-
native or the newAmulet devicemay be used for landing zones up to
31 mm). For both, theWatchman and ACP devices, sizing tables are
available. In general, the device size should at least be 10–20% larger
than themeasureddiameter, although someoperatorsmayprefer up
to 30%. If thedepthof the LAA is smaller than thewidthof theostium,
placementof aWatchmandevicemay result in unstable positionwith
unacceptable device protrusion into the LA. For further information
regarding the sizes and choice of the device, refer to the section
Implantation techniques and to Table 2.
Procedural imaging to guide left atrial
appendage occlusion
Real-time visualization of the LAA for device positioning and deploy-
ment is a key for successful implantation. As long as the total proced-
ure time can be kept short, deep sedation may not be necessary.
However, the majority of centres perform the procedure in
general anaesthesia with 2D TOE in combination with X-ray guid-
ance, while someoperators close LAAs under fluoroscopic guidance
alone to facilitate the logistics (less personnel and no sedation or in-
tubation required).41,78,79 Personnel performing TOE during LAA
occlusion should be well trained and familiar with the procedure
and the required measurements for the type of device used.
Limited data are available on LAA occlusion using ICE, but this may
allow the procedure to be performed under local anaesthesia.80
Reports showed superior visualization of the LAA with the ICE
probe positioned in the LA or pulmonary artery compared with a
position in the right atrium or coronary sinus. To place the ICE
probe in the LA in the absence of a PFO, a second transseptal
passage is required. Left atrial appendage occlusion with ICE should
only be performed by operators with experience in ICE catheter
handling and interpretation of ICE images.
Only 3D TOE can provide a real-time full view of the LAA and im-
portantly, the shapeof theLAAostium.A recent report demonstrated
that 3DTOE-derivedmeasurements of LAA orifice areawere closely
related with CT measurements. In this study, 2D TOE significantly
underestimated LAA dimension and orifice size, as compared with
3D TOE.81 Future studies demonstrating the feasibility and accuracy
of 3D TOE during LAA occlusion procedures are required.
Transoesophageal echocardiography or ICE also facilitate trans-
septal puncture. Most operators prefer an inferoposterior, others a
mid to superior and posterior puncture. This illustrates how variable
the anatomy is. A puncture site superior and anterior is usually sub-
optimal. Therefore, LA access via a PFO (which results in a superior
and anterior path) is avoided by most operators. After positioning a
sheath or pigtail catheter in the LAA, selective contrast injection
under fluoroscopy in RAO caudal and cranial (108–308) projection
gives excellent views of the LAA not overlapping the LA. Final deci-
sion on device size is based on information collectedwith both echo-
cardiography and fluoroscopy. Real-time TOE provides direct
information on the position of the delivery sheath in the LAA and
helps during device deployment. Following successful device deploy-
ment, thepericardium is evaluated foreffusion. Someexperts recom-
mend another echocardiography (TTE usually) to confirm device
position and exclude pericardial effusion prior to discharge. We
are not aware of any information on the yield of such an examination.
Rare device embolizations upon first mobilization of the patient
with change of the heart position have been observed.
Follow-up imaging
Transoesophageal echocardiography is themost revealing technique.
Alternatively, post-procedural imaging to assess device position,
peridevice residual flow in the LAA, and thrombus formation on
the device consists of chest X-ray (position only) or CT. Magnetic
Figure 4 Three-dimensional TOE with live x-plane imaging
allows simultaneous display of the LAA from two views. Measure-
ment of LAA ostium diameter (A) and LAA depth (B) is crucial for
selecting the appropriate device size.
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resonance imaging is hampered by device artefacts. The timing of a
follow-up TOE varies between institutions. Most operators use
early or follow-up echocardiographic findings, i.e. the absence of
large residual flow into the LAA or thrombus, as a guide for prescrib-
ing antithrombotic drugs. In thePROTECTAF (WatchmanLeftAtrial
Appendage System for Embolic Protection in Patients with Atrial
Fibrillation) trial, serial TOE imaging was performed at 45 days,
6 months, and 1 year following implant.45 The logic behind the
timing of the first two examinationswas based on changes inmedica-
tions subsequent to the examination, i.e. warfarin and clopidogrel
were discontinued if TOE showed the absence of thrombus, occlu-
sion of the LAA, or residual peridevice flow of ,5 mm width
(assessed by colour Doppler) at 45 days and 6 months. A sizable
serieswith theACPused a regimenof clopidogrel for 1 and acetylsali-
cylic acid (ASA) for 3 to 6 months.82 Follow-up TOEwas performed
at variable times between 3 and 6 months following implantation.
For patients treated with coumadin and antiaggregants according
to the PROTECT AF protocol, it is prudent to follow the imaging
protocol of the trial, as it serves as a guide to changes in medications.
In other patients who are treated with antiaggregants only, it makes
sense to image prior to cessation of clopidogrel and again if ASA ces-
sation is planned. It is recommended to perform a TOE at 45 days to
6 months after implantation, since most adverse events including
device dislodgement and thrombi were so far documented at the
45-day TOE. The value of additional TOE investigations at later
time points is unclear. In case of a new embolic event, a repeat
TOE is indicated as is the case if a TOE demonstrated a significant
leak or a thrombus on the device (see chapter on Anticoagulation).
Residual peridevice flow is a commonechocardiographic finding in
patients treated with the Watchman device. There is concern that
this could potentially lead to thrombo-embolic events, since new
thrombi may form in the distal LAA pouch as a result of low flow vel-
ocities. In 41% of patients of the PROTECT AF study, this was
observed during TOE at 45 days.83 This decreased to 32% at the
1-year follow-up. The majority of patients had flow jet widths of
1–3 mm.Of note, in patients with peridevice flowwho discontinued
warfarin, the clinical outcome was not affected. Amplatzer devices
have less residual flow because the disc of the device typically
covers the entire LAA ostium (pacifier principle). For further recom-
mendations on antithrombotic treatment in patients with peridevice
flow, we refer to the section on Anticoagulation.
Information is scarce about the role of imaging in Lariat device im-
plantation and follow-up. Transoesophageal echocardiography is
used to verify LAAocclusion during the procedure and for follow-up,
but no clear protocol has been put forward.
Suggested standards for operators
and centres and required
information for registries
and studies
Requirements for operator and centres
Training and knowledge of physicians performing the
procedure
Extensive knowledge of cardiac anatomy, particularly of the LA and
LAA and the surrounding structures is required for operators who
embarkonLAAocclusion.Operatorsmustbe acquaintedwith trans-
septal puncture techniques and with pericardiocentesis as a pre-
requisite to start LAA occlusion training. Experience with other
procedures performed transseptally for an interventional cardiolo-
gist or with LA ablation procedures for an electrophysiologist
should be required to be sufficiently cognizant of LA anatomy and
the anatomical position of LAA in relation to the surrounding struc-
tures.84–86 Operators must be aware of the several LAA anatomical
variations, in terms of size, angulation, and mobility. The procedural
skill is also based upon the operator’s ability to put LAAmorphology
in relation to the technique and the outcome of the procedure. Left
atrial appendage anatomy plays a key role for the selection of the
most adequate occlusion device. The success of the procedure is
closely related to the level of knowledge and experience of each in-
dividual belonging to the team, including the echocardiographer sup-
porting the procedure. The learning curve has to be expected rather
flat in light of the intricacy of the procedure.
A key factor for procedural success is a structured training process
before becoming an independent operator. The training process,
currently provided by the devicemanufacturer, includes basic princi-
ples, specific device features, and the performance of the procedure.
Webelieve that a trainingprocess for implantationof a specificdevice
should include the following:
(1) Theoretical course, often taken on line, teaching anatomy, clinic-
al data, and the theory of device implantation including inter-
active cases. This training stage should also include critical
issues, such as patient and device selection, possible complica-
tions, anddetection andmanagementofmajoradverseevents in-
cluding pericardiocentesis.
(2) Practical training including bench training with handling of the
equipment, and attending live cases at experienced centres, or
interactive during congresses or online. The addition of
hands-on simulator training on several virtual cases is helpful
but should not replace attendance at real cases.
(3) During their first procedures, operators are to be properly proc-
tored at their sites by experienced operators.
Importantly, in addition to the implanters, echocardiographers
involved in patient evaluation for the procedure and echocardio-
graphic support during procedures should be specifically trained
for the respective aspects of the procedure.
Centre and laboratory requirements
Since the procedure is usually performed under general anaesthesia
and TOE guidance, an anaesthesiologist and an experienced echocar-
diographerwhohad specific training in supporting LAAocclusionpro-
cedures should be part of the procedural team. Nursing and technical
personnel should also be familiar with every procedural step, well
accustomed to interventional techniques, and prepared to manage
adverse events and emergency situations. Site readiness for the pro-
cedurenecessitatesnotonlyaknowledgeableoperatorbuta thorough
teamunderstandingof the procedure and of the individual role of each
member of the team. According to current practice in house cardio-
vascular surgery in centres performing LAA occlusion procedures is
not deemed mandatory but arrangements for rapid transfer to a
centre with available cardiac surgery should be available, with a
maximum time of 60 min to reach the operating room.
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Data collection for registries and studies
In light of theworldwide increasing number of LAA occlusion proce-
dures, there is a need to collect extensive information regarding the
number of procedures, criteria of patient selection, acute and long-
term clinical outcome, and the occurrence of any type of complica-
tions.87 Initial clinical data are available from the PROTECT AF45
study and Continued Access Protocol (CAP) study analysis88,89
using the Watchman device. They are, in part, offering randomized
comparisons to warfarin, whereas data about success and complica-
tions rates with the ACP device are entirely based on registries with
indirect comparison to OAC.90 Due to the fact that not all patients
with AF and contraindications to OAC or with serious untoward
effects with OAC are suitable for LAA occlusion, there is a need
for extensive data to guide patient selection. In this regard, studies
should be including multiple centres with proven experience of
each operator with at least 10 proctored and 10 main operator pro-
cedures. While new studies are being designed, there is also a need
for large registries of LAA occlusion. To create large registries,
defined inclusioncriteria among thedifferent centres (e.g.CHA2DS2-
VASCandHAS-BLEDscores) are thebasis. This allowsassessmentof
acute and long-term clinical outcome with respect to several issues,
such as successful implantation, periproceduralor late complications,
rateof neurological cardiovascularevents, and safetyof the approach.
For the purpose of uniformity and ability to compare and group to-
gether results of different registries and studies, Table 3 lists recom-
mended parameters to be collected in LAA occlusion registries.
Clinical results
PLAATO
Several observational human studies using the no longer available
PLAATOdevice have been published.38,43,91–93 In all reports, antiplate-
let therapy only was used after implantation. Invariably, the post-
procedural stroke incidence was lower than projected by the
CHADS2 score for patients treated with ASA only. According to data
from three studies including a total of 359 patients (mean follow-up of
9.6 months, 9.8 months, and 24 months, respectively), the annualized
stroke risks were 2.3, 2.2, and 0.7%, respectively, substantially lower
than the risks predicted based on the CHADS2 score (6.6, 6.3, and
4.9%, respectively).43,92,93 At long-term follow-up (61 patients, mean
follow-up of 5 years), the annual stroke or transient ischaemic attack
rate (3.8%) remained lower than predicted by the CHADS2 score
(6.6%).92 Including data from 364 patients (three studies) with
attempted or successful PLAATO implantation, procedural mortality
and the incidence of pericardial effusion requiring drainage, device em-
bolization, and periprocedural stroke were 1, 2.5, and 0.5% respective-
ly.43,92,93 Hence, though associated with a small risk of major
periprocedural events, the PLAATO device appeared to be effective
in reducing the stroke risk equally or better than OAC in patients
with AF when compared with historical controls of equivalent stroke
risk in a non-randomized fashion.
Watchman
Table 4 summarizes current published and presented clinical experi-
ence with the Watchman device.
First, clinical experience with the device was published in 2007.44
Thereafter, high-risk patients have been enroled into trials and regis-
tries providing data from 1139 patients with over 1500 patient-years
of follow-up. The results demonstrate the safety and efficacy of this
device in preventing thrombo-embolic events compared with war-
farin therapy.45,66,88,89,94–96
The Watchman device is the only LAA occlusion device that
has been evaluated in prospective, controlled, randomized trials
examining its efficacy and safety, e.g. in 707 patientswith non-valvular
AF.45 The PROTECT AF study was designed to assess the non-
inferiority of the device against chronic warfarin therapy. The first
publication included follow-up of 1065 patient-years,45 but data on
1500 patient-years are currently available97 of whom 87% discontin-
ued OAC at 45 days and 94% after 2 years of follow-up. Although
there was a higher rate of adverse safety events in the intervention
group than in the control group, due mainly to periprocedural com-
plications (pericardial effusion and procedural stroke typically
related to air embolism),most eventswerewithout long-termseque-
lae. Safety events in the Watchman group occurred primarily on the
day of the procedure, while the event rate was lower than that of
the control group after the periprocedural period. Importantly,
when follow-up was extended from 600 to 1500 patient-years, there
wasa46%reduction in relative risk from2.85to1.53.Longer follow-up
results were recently presented with a further decrease in primary
event rate and, for the first time, a survival benefit for theWatchman
group when compared with the control warfarin group.96
The effect of increased operator experience is demonstrated in the
CAP registry with shorter implant time, higher implant success rate,
lower complication rates, and higher warfarin discontinuation rate.88
The Randomized Trial of LAA Closure vs. Warfarin for Stroke/
Thromboembolic Prevention in PatientswithNonvalvular Atrial Fib-
rillation (PREVAIL) study66 was designed similarly to strengthen the
results of the PROTECT AF trial in more patients at somewhat
higher risk treated by centres with variable experience. Its prelimin-
ary results, presented but not yet published, demonstrated low early
and long-term primary and safety event rates.
In the PROTECTAF study (average CHADS2 score 2.2 and CHA2-
DS2-VAScscore3.4), all patientswere treatedwithwarfarin for45days
after device implantation to facilitate device endothelialization. War-
farin was stopped if TOE examination (performed after 45 days, 6
months, and 1 year) showed either complete occlusion of the LAA
or if there was residual peridevice flow of ,5 mm in width.
However, recentdata support the safety and efficacyof LAAocclusion
in patients with contraindications to even temporary anticoagulation
treated with antiplatelet therapy only after device implantation.95
Peridevice flow is common after Watchman implantation. In a
retrospective analysis evaluating the clinical impact of incomplete
LAA sealing in patients undergoing percutaneous LAA occlusion
with the Watchman device, some degree of peridevice flow was
reported in47%at45days and33%at12months.However, theover-
whelming majority of leaks were small. Peridevice flow .3 mm was
seen in only 12% of patients at 12 months. Most importantly, com-
pared to patients with complete occlusion there was no difference
in thrombo-embolic events in thosewith any peridevice flow regard-
less of whether or not anticoagulation was continued. Hence, small
amounts of residual flow do not appear to impact safety and clinical
efficacy of Watchman implantation.83 Given the small number of
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Table 3 Parameters for registries of LAA occluders
(1) Demographic data
Name or registry code
Gender
Age
(2) Type of device implanted
Watchman
ACP
Other
Previous failure of LAA occlusion device (type, date, reason)
(3) Type of atrial fibrillation
Paroxysmal
Persistent
Long-standing persistent (permanent)
(4) Cardiovascular history
Ischaemic heart disease
Congestive heart failure
Valvular heart disease
Cardiomyopathy
Arrhythmic history other than AF
(5) CHADS2 score
(6) CHA2DS2-VASc score
(7) HAS-BLED score
(8) Antithrombotic therapy given prior to the implant
ASA
Clopidogrel
Warfarin
Apixaban
Dabigatran
Rivaroxaban
Prasugrel
Ticagrelor
Low-molecular-weight heparin
Fondaparinux
Other
None
(9) Indication for implant
Low compliance
History of intracranial bleeding (intracerebral and subdural)
History of urinary tract bleeding
History of spontaneous bleeding other than intracranial or urinary
tract bleeding (i.e. retroperitoneal haematoma)
Recurrent falls
Cognitive impairment
Use of non-steroidal anti-inflammatory drugs, steroids
Personal preference
(10) Technical data of implant
Success/failure
Size of the device implanted
Measure LAA opening, landing zone, and depth
LAAmorphology (unilobar, multilobar, ‘cauliflower type’, chicken
wing, wind sock, etc.)
Continued
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Continued
Need for device replacement during the procedure (type and size)
(11) Periprocedural complications
Death
Ischaemic stroke
Transient ischaemic attack
Haemorrhagic stroke
Pericardial effusion with tamponade
Valvular complication (i.e. mitral valve damage)
Device embolization
Bleeding
Major
Minor
Peripheral vascular complication
Pulmonary oedema
Myocardial infarction
Arrhythmia (type)
Pulmonary embolism
(12) Antithrombotic therapy at discharge and length of therapy
ASA
Clopidogrel
Warfarin
Apixaban
Dabigatran
Edoxaban
Rivaroxaban
Prasugrel
Ticagrelor
Low-molecular-weight heparin
Fondaparinux
Other
None
(13) TOE follow-up at 6 weeks, 6 months, and 1 year
Device position (as at implant)
Device-related thrombi
Para-device leak (size)
Device embolization
(14) Clinical follow-up at 6 weeks, 12 months, and yearly thereafter
Death
Ischaemic stroke
Transient ischaemic attack
Haemorrhagic stroke
Device embolization
Major bleed
Minor bleed
Peripheral vascular complication
Pulmonary oedema
Myocardial infarction
Arrhythmia (type)
Pulmonary embolism
Type of antithrombotic therapy
ASA, acetylsalicylic acid. Other abbreviations as in Table 2.
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Table 4 Results with theWatchman device
Trial Patients Patients
device/
Control
Comments Average
CHADS2
Score
Average
CHA2DS2-
VASc Score
Medical
therapy
Efficacy events Safety events Successful
implantation
Mean follow-
up (months)
No
warfarin
Primary efficacy
event rate
(per 100
patient-years)
Safety event
rate
Pilot
study44,94
66 66/0 Non-randomized
cohort of patients
undergoing
Watchman
implantation
1.8+ 1.1 Warfarin plus
ASA for 45
days, and
ASA for life
Death, stroke,
systemic
embolism, and
major bleeding
88% 73+ 25 91% Actual stroke rate
of 0.5%
4 device
embolizations
PROTECT
AF45,89
707 463/244
warfarin
Randomized non-
inferiority trial
2.2+ 1.2 3.4 Warfarin plus
ASA for 45
days, DAPT
for 6
months, and
ASA for life
Composite
endpoint of
stroke,
cardiovascular
death, and
systemic
embolism
Device
embolization,
major bleeding
events, and
pericardial
effusion
88% 18+ 1045
43.4+ 21.789
94% 345
389
2.3
745
689
CAP
Registry88
460 460/0 Non-randomized
registry of patients
undergoing
Watchman
implantation
2.4+ 1.2 Warfarin plus
ASA for 45
days, DAPT
for 6
months, and
ASA for life
PROTECT AF
protocol
PROTECT AF
protocol
95% 25.4+ 10.0 95% 2
ASAP Registry48 150 150/0 Treat patients
contra-indicated
for warfarin
2.8 4.4+ 1.7 DAPT for 6
months and
ASA for life
Stroke rate per 100
patient-years
95% 100% 2
Prevaila 407 269/138 Similar to PROTECT
AFa with revised
inclusion criteria
2.6+ 1.0 Similar to
PROTECT
AF
Stroke, embolism,
or unexplained
death
Same as
PROTECT AF
within 7 days
95.1% Modelled to 18
months, only
58 actually
reached
18 months
1 4
DAPT, dual antiplatelet therapy; ASA, acetylsalicylic acid; AF, atrial fibrillation.
aPrevail data are preliminary and final validation is not yet complete.
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patients with large residual leaks, however, the safety of discontinu-
ation of anticoagulation under these circumstances remains unclear.
Gangireddy et al.89 performed an analysis of the net clinical benefit
(difference between the annualized rate of serious events in theWatch-
man group and the rate in thewarfarin group, assigning different weight
to the events according to severity) of Watchman implantation in
PROTECT AF and CAP. This analysis demonstrated an increased net
clinical benefitwithhigherCHADS2 scores, especiallywhen theWatch-
mandevicewasused for secondary prevention inpatientswith previous
events.89 The device was also effective in improving quality of life com-
pared with warfarin therapy.97 It was cost-effective when compared
with warfarin but only marginally sowhen comparedwith dabigatran.98
Two ongoing studies are evaluating the device in several hundred
additional patients.
Amplatzer Cardiac Plug and other
Amplatzer devices
Amplatzer devices implanted into the human atria look back atmore
than a 20-year history in over amillion patients. They have a lowpro-
pensity for device thrombosis (,1%) in patients with sinus rhythm.
This track record together with their ease of use led to their utiliza-
tion for percutaneous LAA occlusion41 only a few months after the
first percutaneous LAA occlusion procedure was performed with
the PLAATO device.38 With the PLAATO device withdrawn, the
Amplatzer devices have the longest clinical follow-up of currently
available LAA occluders.79
Non-dedicated Amplatzer devices
Experience with ASD occlusion permitted the use of Amplatzer
devices for LAA occlusion under fluoroscopic guidance only.41,79
However, the lack of retaining hooks and suboptimal sheath config-
urations resulted in a high embolization rate (6% in the aforemen-
tioned studies). Most embolized devices were retrieved
percutaneously, but in some cases surgical removal (combined
with LAA occlusion) was carried out. None of the available Amplat-
zer devices designed for occlusion of atrial or ventricular septal
defects, patent ductus arteriosus, or vascular shuntsproved adequate
for LAA occlusion. Therefore, a specific mould was developed con-
sisting of a hooked lobe, a thin connector, and a proximal disc. The
latter is a remnant of the initial double-disc devices and comes in
handy to cover the orifice of the LAA (pacifier principle). The clinical
outcome in patients with technically successful Amplatzer LAA
occlusion was rewarding with 0.5 events per 100 patient-years com-
pared with the expected 5.5 events without anticoagulation or 1.8
events with anticoagulation according to the CHADS2 score.
99 All
patients in this series were discharged on antiplatelet therapy only.
These results have to be put into perspective of a rate of 1% no
device implanted and 4% device embolization. Interestingly and
somewhat surprisingly, there were no device embolizations in
patients with sinus rhythm at the time of implantation.
Amplatzer Cardiac Plug
Since 2008, the dedicated ACP device with lobe sizes of 16–30 mm
diameter (disc diameter slightly larger) and a dedicated double
curve sheath with a modified pusher cable have been used almost
exclusively. Initial registry data reflected the technical improvements
with a reduction of the embolization rate to 2%48,68,79,99–105
(Table 5). Pericardial effusion leading to cardiac tamponade requiring
interventions occurred in 2% as did neurological events. These
figures are comparable with those obtained with the PLAATO43 or
the Watchman devices.45,88 In contrast to the Watchman device,
there are hardly any anatomical contraindications (with the excep-
tion of visible mobile thrombus) for an attempt at LAA occlusion
with an ACP. Technical success in the first 200 registry patients was
97% and a relevant thrombus on the device during follow-up TOE
was seen in 3%. The complete occlusion rate at 6-month TOE
was 99%. This is considerably higher than what was achieved with
the Watchman device. The difference can be explained by the ACP
disc occluding the mouth of the LAA in addition to the plug in the
neck (feature sharedwith theWatchman device). Long-term follow-
up data are lacking but design andmaterial of the ACP are so close to
that of non-dedicated Amplatzer devices that clinical outcomes can
be expected to be superimposable to those mentioned in the para-
graph above and perhaps even competitive to non vitamin K oral
anticoagulants (NOACs).79
Even with the user-friendly Amplatzer technique, LAA occlusion
remains challenging and the learning curve is everything but steep,
much in contrast to that of occlusion of the PFO. Notwithstanding,
with growing experience the results improve. Technical modifica-
tions (more and stronger hooks, deeper lobe) and the tendency to
implant largerdevicesmoredeeply should lead to improved technical
results. Generally ACPs are implanted without OAC thereafter. The
observed thrombosis rate still leaves roomfor improvement so that a
brief period of (N)OACs in patients without a contraindication may
be part of future protocols.
LARIAT technique
There are but preliminary data on the use of Lariat technique. A re-
cently published series described the results in 89 patients with
96% implant success, with 3 access related complications. Long-term
follow-up revealed severe pericarditis, late stroke, and sudden death
in two patients each and late pericardial effusion in one patient.106
Indications for left atrial appendage
occlusion
The recommended indications for theuseof LAAoccluders are sum-
marized in Figure 5. In accordance with ESC guidelines, we use the
CHA2DS2-VASc risk score (.1) as the threshold value for LAA
occlusion, despite the fact that some of the evidence (mainly
related to the Watchman device) Is based on CHADS2 scores
≥1.107 We believe that both these definitions may be used.
As alternative to oral anticoagulation
when oral anticoagulation is possible
Although this population constitutes a small minority of LAA occlu-
sion recipients today, this is the only indication that is currently based
on randomized controlled data and was recently recommended by
an FDA panel for approval. Contrary to FDA opinion and emerging
report on the cost-effectiveness of LAA occlusion,98,108 the British
National Health Service Commissioning Board ruled that the cost-
effectiveness and clinical effectiveness of the device are not estab-
lishedenoughyet, and therefore thedevice is not funded in theUK.109
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Table 5 ACP registries in comparison with PROTECTAF
In-hospital Follow-up
Registry Patients Mean
age
(year 5)
Mean
CHADS2
score
Technical
success
Stroke Pericardial
effusion
conservative
Tamponade
(Drainage)
Device
embolization
Death
(all cause)
Total
adverse
events
Device
embolization
Pericardial
effusion
Thrombus
on device
Stroke Death
Italian
Registrty101
100 100/100 0 2/100 0 0 2/100
100% 2% 2%
Dual Centre,
Hamburg
Bern97
131 131/131 0 1/131 0 0 0 1/131
100% 1% 0.8%
ACP EU Post
Market
Registry98
204 74+9 2.6+1.3 197/204 0 3/204 3 0 6/204 1 0 5/204
97% 1.5% 2.9% 2.4%
Spanish
Registry99
35 75+6 2.4+1.3 34/35 0 0 0 0 0 0 0 0 5/35 1/35 3/35
97% 14% 3% 9%
Initial
European
Experience48
143 74+9 – 132/137 3/143 4/143 5/143 2/143 0 10/143
96% 2.1% 3% 3.5% 1.4% 7%
Bern LAA
Occlusion
Registry100
100 72+10 2.5+1.3 98/100 1/100 2/100 1/100 2/100 0 6/100
98% 1% 2% 1% 2% 6%
Initial Asian
Experience68
20 68+9 2.3+1.3 19/20 0 0 0 0 0 * – – – – –
95%
Canadian
Registry105
52 74+8 3 (2–4) 51/52 0 1/52 1/52 1/52 0 2/52 0 1/52 0 1/52 3/52
98% 2% 2% 2% 4% 2% 2% 6%
PROTECT AF45 463 72+9 2.2+1.2 408/463 5/463 8/463 22/463 3/463 0 36/463 2/463 0 16/694
2.3%
21/705
88% 1% 1% 5% 1% 8% 0.4% 3.0%
*Air embolism in right coronary artery, one oesophageal injury during TOE.
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When patients are eligible for OAC and do not exhibit an
increased risk for bleeding, it is the consensus of the writing commit-
tee that the option of LAA occlusion should be mentioned to the
patient while OAC currently remains the standard of therapy. Left
atrial appendageocclusion shouldnotbepresented as superior treat-
ment at this stage. Instead, the advantages and disadvantages of both
treatments should be explained in detail emphasizing that rando-
mized data currently are limited to two studies with a single device
comparing it with a single agent (warfarin), an oral VKA.45,66 As far
as devices other than Watchman are concerned, they are based ex-
clusivelyonobservational studies. Long-termoutcomeafter LAAoc-
clusion (taking into account periprocedural adverse events) was
shown equivalent or according to the 4-year results of the
PROTECT AF study even superior (in terms of stroke prevention
and survival) to anticoagulation with warfarin. Yet, serious complica-
tions related to the procedure itself (including, but not limited to, the
risk of death, stroke, and emergency surgery) occur. Finally, patients
should be educated that NOACs are available that, compared with
oral VKAs, has at least equivalent and probably improved efficacy.
All tested NOACs compounds have a lower rate of intracranial and
some also of overall risk for haemorrhage and they are free of the lo-
gistical challenges associatedwith surveillance of therapeutic levels. It
should be emphasized that none of them has so far been compared
with LAA occluder devices while there are ample data to show
that they are equal or better than VKAs. Hence, they should be con-
sidered and discussed as an important preventive treatment alterna-
tive with much more supporting evidence than LAA occluders.
Ultimately, the decision should be made by a well-informed patient
in collaborationwith the treatingphysician(s). It shouldbementioned
that for this indication the only device that has evidence-based
support for its use is the Watchman device, whereas other devices
were not systematically studied in a randomized controlled fashion.
As replacement for anticoagulation when
anticoagulation is not possible
Patients with a contraindication to anticoagulation
Patients with a high thrombo-embolic risk (CHA2DS2-VASc score
of .2) but contraindication to oral and systemic anticoagulation
(e.g. history of a significant bleeding event such as intracranial or life-
threatening bleeding, the source of which cannot be eliminated)
represent the most accepted clinical indication for LAA occlusion,
albeit by having to extrapolate the results of the PROTECT AF
study to that specific cohort.110 So far, no randomized data targeting
this specific group of patients are available. Hence, our statement is
based on expert consensus. This is the result of several observational
studies and registries (described above in the sections dedicated to
the Watchman and Amplatzer devices) suggesting that occlusion is
Suitable for OAC Increased risk for bleeding
Atrial fibrillation patient with indication for OAC for stroke/embolism prevention (CHA2DS2-VASc > 1)*
Patient refusal of OAC
despite adequate
information
1. Contraindication for
    systemic (N)OAC
2. Refusing systemic
    (N)OAC after
    adequate information
    and physicians advice
LAA occlusion
(includes the need
for antiplatelet
therapy)
NOAC
OAC, preferable NOAC
Mention LAA occlusion
Acceptable risk for systemic
(N)OAC?
YES
No
No treatment vs. LAA occlusion
Individual risk/benefit evaluation for
(N)OAC vs. alternative methods
1.   HAS-BLED score ≥ 3
2.   Need for a prolonged triple anticoagulation therapy (e.g.
      recent coronary stents)
3.   Increased bleeding risk not reflected by the HAS-BLED score
      (e.g. thrombopenia, cancer, or risk of tumour associated
      bleeding in case of systemic OAC)
4.   Renal failure (severe) as contraindication to NOAC
*In all: adequate and intensified rhythm control (ablation or amiodarone) in combination with continuous rhythm control by implanted devices with remote monitoring.
Advise NOAC
Figure 5 Algorithm of stroke protection in atrial fibrillation. LAA, left atrial appendage; NOAC, novel (non-Vitamin K antagonist) oral anticoagu-
lant; OAC, oral anticoagulant.
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safe and effective despite the absence of even temporary (N)OACs. It
should be noted that dual antiplatelet therapy (DAT) is generally indi-
cated for1–6months, not infrequently followedby lifelongsingleanti-
platelet therapy. It needs tobementioned thatDATgenerates amajor
bleeding risk comparable to that of warfarin.111 However, DAT ex-
posure following LAA occluder implantation is only short time, thus
reducing the cumulative risk of major bleeding events. Even when
single-centre experience is reporting a favourable outcome after ter-
mination of any antiplatelet therapy, the majority of patients are
exposed to a long-lasting single antiplatelet therapy after occluder im-
plantation, again having thedisadvantageof inducing amajor and intra-
cranial bleeding riskswhile, e.g. onASA, similar to thosewithwarfarin
when stratified by the HAS-BLED score.112 In patients who cannot
receive any antiplatelet agent, transepicardial LAA ligation, e.g. with
the Lariat technique can be considered.
Patients with an increased bleeding risk under systemic
anticoagulation
As depicted in the flow chart (Figure 5), we see the following three
patient groups as possible candidates for LAA occlusion as the
result of an individual risk benefit evaluation recognizing that the pri-
marily recommended strategy is the use of OAC:
(1) In general, patientswith an increasedHAS-BLEDscore should be
individually evaluated as to whether systemic OAC subjects
them to an unacceptable bleeding risk and whether this high
risk can be sufficiently reduced by the use of appropriately
dosed NOACs (discussed below) shown to be associated with
a lower bleeding risk than VKAs. Those in whom VKAs or
NOACs are still considered to pose an unacceptable bleeding
risk, but who remain at high stroke risk (CHA2DS2-VASc score
of .2), should be considered for LAA occlusion. More detailed
information to perform an individual risk evaluation were
discussed by Friberg et al.112 and Oleson et al.113
(2) Triple anticoagulant therapy causes a significant rise in bleeding
risk.114–116 Hence, in patients with the need for a prolonged
periodof triple anticoagulant therapy as a result of severe coron-
ary artery disease treated with one ormore stents and AFwith a
high thrombo-embolic risk (CHA2DS2-VASc score of .2)
should be considered for percutaneous LAA occlusion.
(3) In clinical practice on a case-by-case basis, some patients with
high bleeding risk who are not well characterized by the
HAS-BLED score (e.g. patientswith cancer or chronic inflamma-
tory bowel disease) but have a high risk of bleeding with OAC
may also be considered for LAA occlusion provided even
NOACs be deemed to be associated with an unacceptable
bleeding risk.
(4) In patients with end-stage renal failure, high stroke risk, and high
bleeding risk, the implantation of an LAA occluder is a debatable
alternative. In those patients, all NOACs are contraindicated
at a creatinine clearance ,15 mL/min. The benefit of VKA or
NOACs in renal failure with creatinine clearance ,15–30 mL/
min is questioned due to elevated bleeding risks. The use of
VKAs in patients with renal failure is controversially discussed
due to an increase in tissue calcification and enhanced
atherosclerosis.
Importantly, for all four above groups, we recommend the perform-
ance of an individualized risk/benefit analysis for NOACs and to
consider LAA occlusion as an alternative to anticoagulation. For
this analysis, it should to be taken into account that at least 1–6
months of either OAC or DAT are warranted after LAA occlusion.
Thereafter, patients are typically treated with at least one antiplate-
let agent. Therefore, the bleeding risk for ASA (as documented, for
example, in the Apixaban versus Acetylsalicylic Acid to Prevent
Strokes (AVERROES) trial)117 has to be included into the LAA oc-
clusion strategy discussion. However, the notion that, beyond the
post-procedural period, indefinite single antiplatelet therapy pre-
vents thrombo-embolic events related to the device itself is not
evidence-based, but merely the result of the assumption that
many patients have concomitant risk factors for atherosclerosis
and stroke irrespective of AF and any foreign body continues to
pose some risk of thrombus formation even beyond expected in-
corporation into the surrounding tissue.
As a complement to anticoagulation
The combination of LAA occlusion and OAC is discussed and occa-
sionally performed in patients with embolic events despite adequate
OAC provided no other plausible cause (e.g. carotid disease,
severe mobile aortic arch atheromata) can be identified. The ESC
guidelines107 recommended approach is increasing the international
normalized ratio (INR) target 2.5–3.5 in this situation,when it occurs
while taking warfarin. Another discussed option is the switch from
VKA to one of the NOACs.118–121 Adding an antiplatelet agent to
OAC is performed in the clinical arena, especially when embolism
occurred at elevated INRs or while taking NOACs; however,
there are no data available demonstrating a positive effect on
embolic events which would support this approach. Left atrial
appendage occlusion could be debated as an alternative treatment
in those patients, especially when AF-related embolism occurs
while taking VKA with documented elevated INRs or switching to
NOACs is not possible due to a NOACs contraindication like
severe renal impairment.
As adjunct to ablation of atrial fibrillation
So far, fewdata on the combinationof LAAocclusion andAF ablation
in a single session have been published.122 Additional personal com-
munications about limited single-centreexperiences still donotallow
a general recommendation. However, as long as no randomized data
to support a significant reduction in thrombo-embolic events after
successful ablation are available, in very select cases, this combination
seems to be a valuable and practical approach: patients with a signifi-
cant risk of thrombo-embolic events (CHA2DS2-VASc score of.2)
undergoing an ablation procedure to treat symptomatic AF, who, in
addition, have a strict or relative contraindication to (N)OACs,might
be acceptable candidates. Under these circumstances, the ablation
itself is associated with the risk of transseptal puncture, perhaps
general anaesthesia, and anticoagulation and the incremental proced-
ural risk of LAAocclusion is substantially lower than if performed as a
standalone procedure even though the overall procedure is becom-
ing longer. However, once again, patient preference after thorough
discussion pointing out the absence of data supporting this strategy
must be integral part of the decision-making process.
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In the era of new anticoagulants
There are no scientific data available directly comparing LAA occlu-
sion toNOACs.Though intracranial haemorrhagemaybe lowerwith
dabigatran 150 mg orally twice daily121 or rivaroxaban 20 mg orally
once daily,120 the overall incidence of major bleeding remains
similar to VKAs. Therefore, in the absence of further data, it is the
opinion of this consensus panel that, at the aforementioned doses,
contraindications to VKAs apply equally to dabigatran and rivaroxa-
ban, andotherNOACs (Figure5).As anexception, low-dose (110 mg
orally twice daily) dabigatran or apixaban119 have been associated
with lower rates of overall major bleeding as well as intracranial
haemorrhage compared with VKAs while maintaining equivalent ef-
ficacy in stroke prevention.121 Therefore, consideration of low-dose
dabigatran or apixaban may be reasonable in patients at increased
bleeding risk provided inclusion criteria for pivotal trials examining
dabigatran or apixaban are met. A decision should be made on
case-by-case basis carefully evaluating potential bleeding sources
and risks and recognizing limitations (among others, the unclear
safety in patients with renal dysfunction and the absence of a differ-
ence in gastrointestinal haemorrhage). In addition, currently the
safety of triple therapy using any of the NOACs compared with
warfarin remains tobedetermined. In fact, thebleeding risk reduction
of dabigatran in combination with clopidogrel and ASA was only
minor compared with triple therapy including warfarin.121 Though
there are clear advantages both in the logistics of administration
and surveillance as well as the safety and efficacy with NOACs, a
head-to-head comparison to LAA occlusion has not yet been done
and final conclusions favouring NOACs over LAA occlusion or vice
versa cannot be made.
Anticoagulation
AlthoughLAAocclusion is originallymeant as a substitute for chronic
OAC among AF patients, the selective application of anticoagulants
including antithrombotics and antiplatelets for various procedure-
and device-related indications remains essential. Since a majority of
patients subjected to LAA occlusion are at high risk for bleeding,
the anticoagulation regimen should be tailored individually.
Before implantation
Mobile thrombi visualizedby screeningTOEare considered acontra-
indication to catheter-based LAAocclusion. In such cases,≥4weeks
of (N)OACs may allow thrombus resolution to be documented on
repeated TOE before catheter-based LAA occlusion is attempted.
During implantation
Femoral venous puncture by itself does not necessitate anticoagulant
therapy withdrawal. Nevertheless, most operators aim for a normal
INR at the timeof the procedure and use intravenous antithrombotic
agents (mostly unfractionated heparin) during the procedure
(Table 6). The antithrombotic protocol of the PROTECT AF
study,45mandated an INR, 2.0 at the time of procedure. Acetylsali-
cylic acid 81–325 mg was begun at least 1 day before the procedure
and weight-adjusted heparin (70–100 IU/kg) was administered after
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 6 Anticoagulation during and after LAA occlusion
Device/
patient
Heparin
(ACT ≥ 250)
Low-molecular-
weight heparin
ASA Warfarin Clopidogrel Comments
Watchman/
Low
bleeding
risk
Prior to or
immediately
after
transseptal
punctures
Post-procedure till
INR ≥ 2
Load 500 mg prior
to procedure if
not on ASA,
continue 100–
325 mg/day
indefinitely
Start after
procedure INR
2–3 till 45 days
or continue till
adequate
occlusiona by
TOE
Start when warfarin
stopped continue till
6 months after the
procedure
Some centres do not
withhold warfarin and
perform procedure
on therapeutic INR
(no data to support or
dispute this approach)
Watchman/
High
bleeding
risk
Prior to or
immediately
after
transseptal
puncture
None Load 500 mg prior
to procedure if
not on ASA,
continue 100–
325 mg/day
indefinitely
None Load 300–600 mg prior
to procedure if not
on clopidogrel,
continue 1–6
months while
ensuring adequate
occlusiona
Clopidogrel often given
for shorter time in
extremely high-risk
situations.
Clopidogrel may
replace long-term
ASA if better
tolerated
ACP Prior to or
immediately
after
transseptal
puncture
None Load 500 mg prior
to procedure if
not on ASA,
continue 100–
325 mg/day
indefinitely
None Load 300–600 mg prior
to procedure if not
on clopidogrel,
continue 1–6
months while
ensuring adequate
occlusiona
Clopidogrel often given
for shorter time in
extremely high-risk
situations.
Clopidogrel may
replace long-term
ASA if better
tolerated
ACT, activated clothing time; INR, international normalized ratio.
aLess than 5 mm leak.
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transseptal puncture tomaintain an ACT. 200 s for the duration of
theprocedure.123However, someoperators perform theprocedure
while patients are on OACwith a therapeutic INR, an approach that
can neither be supported nor condemnedby currently available data.
Intravenous antithrombotics are generally administered at the latest
immediately after traversing the interatrial septum. A weight-
adjusted bolus of unfractionated heparin (70–100 IU/kg) is most
commonly used, which should maintain an ACT ≥ 250 s. Left atrial
appendage occlusion may be performed as part of a combined
procedure for which another antithrombotic is being used, e.g. biva-
lirudin. This requires no further anticoagulation.
After implantation
Post-procedural anticoagulation with warfarin is recommended
for the Watchman device to avoid thrombus formation on the
device until completion of endocardialization, provided there are
no contraindications to anticoagulation. The anticoagulation proto-
col of the PROTECT AF trial (OAC for 6 weeks, DAT for 6
months, and ASA for life) was adopted in the instructions for use
of the Watchman device. All patients enroled in the PROTECT AF
study had to be eligible for warfarin to enable randomization to
either a Watchman device occlusion or chronic warfarin therapy.
However, this circumstance is rather atypical for patients considered
for LAA occlusion in clinical practice. A considerable proportion of
them have had a bleeding complication or have a contraindication
to chronic anticoagulation (VKA or NOACs), under which circum-
stances operators refrain from implementing a drug regimen includ-
ing an oral antithrombotic and directly prescribe DAT for at least
1month or until a 6-month TOE follow-up, modifying the anticoagu-
lant therapy upon its result. A satisfactory result on TOE (complete
LAA occlusion or small residual shunt ,5 mm jet width in the
absence of device surface thrombi) justifies withdrawing at least
one antiplatelet agent, unless otherwise indicated. Usually the
other antiplatelet agent is continued indefinitely, as most patients
are elderly with evidence of atherosclerotic disease, although the
bleeding risk of ASA even as a standalone therapy must be consid-
ered. This treatment rationale of DAT was mainly derived from pre-
vious experience with the PLAATO device as well as ASD and PFO
device occlusions and was recently confirmed by the results of the
ASA-Plavix (ASAP) registry.95 In patientswhounderwentWatchman
implantation in the ASAP registry and received clopidogrel for
6 months and ASA indefinitely without OAC, the ischaemic stroke
rate was only 1.7% compared with 2.2% in the PROTECT AF
device group. By arbitrary practice, it is usual to loadASA or clopido-
grel naı¨ve patients accordingly (Table 6).
The ACP banks on the good record regarding low thrombogen-
icity of theAmplatzer device family,124 and indicates in its instructions
for use DAT only without an oral anticoagulant. The safety and feasi-
bility of this drug regimen was shown in initial registry data for the
ACP.48
In a recently published study using the Lariat device among 89
patients, those with a contraindication to warfarin remained off war-
farin, while patients with a CHADS2 score of 2 who could tolerate
warfarin but had been non-compliant or had labile INR continued
warfarin. Warfarin use in patients with a CHADS2 score of 1 was
left to the discretion of the referring physician. For patients not on
warfarin, ASA was recommended. At 1-year follow-up, 55% of
patients were still on warfarin.106
Long-term
Transoesophageal echocardiography follow-upperformedafter4–6
months is highly recommended to verify outcome and define the
further anticoagulant regimen. In addition, in patients with clear con-
traindications towarfarin it is often not possible to use warfarin even
for short periods of time and they undergo device implantation
followed by antiplatelet therapy only. Therefore, consideration
should be given to TOE follow-up at 1 month as, theoretically, this
is the crucial period for device-associated thrombus formation.
In case of thrombus on the device
Device-associated thrombus was observed in 20 of 478 successfully
implanted with a Watchman device (4.2%) in the PROTECT AF
trial.88 Of these patients, however, only three had ischaemic strokes
(thrombus-associated annualized stroke rateof0.3/100patient-years).
The remainder were asymptomatic. The device-associated thrombus
was mobile in 4 patients (3 pedunculated and 1 laminar) and non-
mobile in 10. In the remaining patients, the thrombus was not
further characterized. Of the three patients with a device thrombus
and a stroke, one occurred in a patient with a mobile, pedunculated
thrombus. For the ACP, individual cases of device-related thrombi
seen on routine TOE have been described.125 For both devices,
OAC for a period of weeks to months effect thrombus resolution in
most cases. Therefore, anticoagulant therapy is recommended in all
patients with device-associated thrombus regardless of symptoms
until thrombus resolution is confirmed by follow-up TOE.
In case of incomplete occlusion of the left
atrial appendage
Incomplete LAA occlusion could create a thrombus containing
pocket allowing emboli to enter the systemic circulation potentially
causing strokes. Based on PROTECT AF data, small residual shunts
with a jet diameter ,5 mm are usually deemed irrelevant and may
close spontaneously with time. They do not warrant further drug
or device interventions. At 45 days, 14% of the PROTECT AF
cohort had residual flow .5 mm, in whom warfarin was continued
per protocol. At the 6-month TOE, the prevalence of large
(≥5 mm) residual leaks decreased to 8%. Persistent large shunts
are becoming rare with increasing operator experience and can
usually be avoided by proper initial sizing and implantation techni-
ques. Generally, when all patients with residual shunts are included
into one subgroup, the stroke risk is no different compared with
patients in whom the LAA is completely occluded regardless of
whether or not anticoagulant therapy is continued.83 However,
whether persistent large (≥5 mm) shunts deserve long-term
(N)OACs or second occlusion attempts using dedicated or non-
dedicated occlusion devices remains at the operator’s discretion.
Summary, conclusions, and
recommendations
Left atrial appendage occlusion as a means to prevent thrombo-
embolism in AF is based on the observation that the majority of
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thrombi in non-valvular AF form in this cul de sac structure. Left atrial
appendage occlusion using interventional techniques has been
demonstrated to be equivalent to oral VKAs in reducing thrombo-
embolic events.
Clinical evidence
Current commercially available devices include the ACP and the
Watchman and WaveCrest devices as well as the Lariat technique
for percutaneous endocardial/epicardial ligation. All have shown effi-
cacy and relative safety in achieving the goal of preventing thrombo-
embolism in AF patients who do not wish or cannot receive OAC.
TheWatchmandevicehasdemonstratednon-inferiority and later su-
periority when compared with warfarin in a controlled randomized
trial (PROTECTAF).45 The results seem to improve with increasing
operator experience. Patients who are at high risk or cannot receive
OAChave been treated successfully with LAAocclusion followed by
antiplatelet therapy only in observational studies and registries with
results comparable to the PROTECT AF trial.
Standards of performance and
documentation
The procedure requires training and knowledge acquired by a struc-
tured mentoring process. Moreover, institutions entering this field
should have appropriate echocardiography and anaesthesia
support and, preferably also surgical backup. Operators must have
experience with pericardiocentesis and autotransfusion to manage
pericardial haemorrhage and tamponade. Registries are required to
document implantation results, complications, and follow-up.
Imaging
Two-dimensional TOE is currently the standard imaging technique in
selection of patients and follow-up assessments and, as a comple-
ment to fluoroscopy, in device sizing and selection and procedural
guidance. The purpose of follow-up TOE (recommended at, e.g. 45
days, or 3–6 months) is to detect leaks and thrombi on the device.
Whether other modalities such as 3D TOE or ICE, and CT or MRI
will partially replace 2D TOE in the future for these purposes
remains to be determined.
Medical therapy
The procedure is performed under full anticoagulation. Standard
medical treatment followingWatchmandevice implantation includes
a VKA for at least 6weeks followed byDAT for 6months and a single
antiplatelet drug thereafter. However, recent data suggest that
Watchman implantation followed by antiplatelet therapy only (in
the absence of OAC) can also be performed safely in patients at
high bleeding risk. Most ACPs were implanted with DAT for
several weeks to months and a single antiplatelet drug or nothing
thereafter. Prolonged (N)OACs are indicated in case of a
device-associated thrombus or large (≥5 mm) leak.
Indications
Despite the results of the PROTECT AF trial, OAC (with VKA or
NOACs) remains the standard therapy when there is no special
risk or contraindication to (N)OACs. However, the option of LAA
occlusion should be discussed with the patient, including risks of
the procedure and limited proof of superiority. Patients who refuse
(N)OACs after thorough discussion of current data including limita-
tions may be considered for LAA occlusion. The main indication for
LAA occlusion today is a relative or absolute contraindication to
(N)OACs in patients with AF and a CHADS2 score of ≥1 or CHA2-
DS2-VASc score≥2. It is important to realize that this recommenda-
tion is based on observational studies and registries only. With
increasing thrombo-embolic risk, the use of LAA occlusion
becomes more attractive. To be a candidate for LAA occlusion,
patients should be able to receive at least several weeks of DAT fol-
lowed inmost cases by lifelong single antiplatelet drug therapy. If anti-
platelet therapy is not an option, percutaneous endocardial/
epicardial or minimally invasive surgical epicardial LAA occlusion
may be alternatives. The use of LAA occlusion as adjunct to AF abla-
tion and as a supplementOACseems tobe reasonablebut remains to
be explored.
Need for future research
Several issues regarding LAA occlusion remain to be studied. The
ACP and the WaveCrest device have yet to be studied in a rando-
mized controlled trial. No device has been adequately studied in a
randomized controlled fashion in a population at high risk that
cannot receive (N)OACs. None of the devices has been directly
compared with N NOACs. These knowledge gaps should stimulate
further trials to clarify best practice under these circumstances. An
LAA occlusion registry should be established by the European
HeartRhythmAssociation (EHRA) andEuropeanAssociationof Per-
cutaneous Coronary Interventions (EAPCI) of the ESC to document
real-world results of implantation and follow-up and to complete
data on indications that are not well represented in current trials.
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